European Journal of Clinical Investigation最新文献

筛选
英文 中文
Proteomic signatures to detect unilateral primary aldosteronism in hypertensive patients. 检测高血压患者单侧原发性醛固酮增多症的蛋白质组学特征。
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-29 DOI: 10.1111/eci.70081
Cheng-Hsuan Tsai, Po-Hsin Kong, Chen-Chan Hsieh, Yen-Chun Huang, Hao-Min Cheng, Chi-Sheng Hung, Chin-Chen Chang, Jeff S Chueh, Anand Vaidya, Vin-Cent Wu, Chen-Chung Liao, Yen-Hung Lin
{"title":"Proteomic signatures to detect unilateral primary aldosteronism in hypertensive patients.","authors":"Cheng-Hsuan Tsai, Po-Hsin Kong, Chen-Chan Hsieh, Yen-Chun Huang, Hao-Min Cheng, Chi-Sheng Hung, Chin-Chen Chang, Jeff S Chueh, Anand Vaidya, Vin-Cent Wu, Chen-Chung Liao, Yen-Hung Lin","doi":"10.1111/eci.70081","DOIUrl":"https://doi.org/10.1111/eci.70081","url":null,"abstract":"<p><strong>Context: </strong>Primary aldosteronism (PA) is a major cause of hypertension and cardiovascular disease; however, diagnosing PA remains challenging.</p><p><strong>Objective: </strong>We investigated whether deep proteomic analyses could be used to diagnose unilateral PA in hypertensive patients.</p><p><strong>Methods: </strong>We enrolled 52 patients with unilateral PA and 46 with essential hypertension (EH) and divided them into training and validation cohorts. Plasma samples were collected at baseline from all patients and again from PA patients after adrenalectomy. Deep proteomic analysis was performed to identify peptide signatures used to develop a classification model distinguishing PA from EH in the training cohort. The classification model was subsequently tested in the validation cohort and post-adrenalectomy PA patients.</p><p><strong>Results: </strong>After proteomic analysis, six peptide features including HBB, FIBA, Complement CO7, ALBU, C4BPA, and A2AP were selected to generate risk scores and develop a classification model for distinguishing unilateral PA from EH. Risk scores were significantly higher in PA patients compared to those with EH. The classification model had a sensitivity and specificity of 80.5% and 83.3%, respectively, for diagnosing unilateral PA in the training cohort, and 81.8% and 80.0% in the validation cohort. The model demonstrated strong performance with an area under the curve of .92 for distinguishing hypertensive patients with or without PA. Post-unilateral adrenalectomy, the risk scores showed a significant decrease.</p><p><strong>Conclusions: </strong>Proteomic analysis can identify peptide signatures that effectively distinguish unilateral PA from EH. These findings underscore the potential utility of proteomics as an adjunct diagnostic and monitoring tool in the clinical management of PA.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70081"},"PeriodicalIF":4.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardioprotective effects of the extracellular chaperone clusterin in acute myocardial infarction. 细胞外伴侣聚集蛋白在急性心肌梗死中的心脏保护作用。
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-26 DOI: 10.1111/eci.70076
Louwana Allawa, Antoine Poirier, Pascale Pignon, Justine Beaumont, Lucie Lebeau, Agnès Barbelivien, Thomas Bochaton, Céline Beauvillain, Daniel Henrion, Yves Delneste, Pascale Jeannin, Fabrice Prunier, Sophie Tamareille
{"title":"Cardioprotective effects of the extracellular chaperone clusterin in acute myocardial infarction.","authors":"Louwana Allawa, Antoine Poirier, Pascale Pignon, Justine Beaumont, Lucie Lebeau, Agnès Barbelivien, Thomas Bochaton, Céline Beauvillain, Daniel Henrion, Yves Delneste, Pascale Jeannin, Fabrice Prunier, Sophie Tamareille","doi":"10.1111/eci.70076","DOIUrl":"https://doi.org/10.1111/eci.70076","url":null,"abstract":"<p><strong>Background: </strong>Acute myocardial infarction (AMI) remains one of the leading causes of mortality worldwide. Recently, a cardioprotective effect of clusterin (CLU), a ubiquitous extracellular chaperone, has been reported. However, the underlying mechanisms remain unresolved. We hypothesized that CLU exerts its protective effect on AMI by neutralizing cytotoxic and proinflammatory properties of extracellular histones, a new class of damage-associated molecular patterns (DAMPs), that are released after massive cell injury.</p><p><strong>Methods and results: </strong>In vitro, we showed that exogenous CLU reduces histone-induced cell death in H9C2 cells after hypoxia-reoxygenation (.78 ± .15 vs. 1.39 ± .20; p = .0059). Moreover, we found increased CLU protein levels in the ischemic zone vs. non-ischemic zone after AMI in mice (p < .05). Correspondingly, CLU-deficient (CLU<sup>-/-</sup>) mice presented significantly increased infarct size vs. wild-type (CLU<sup>+/+</sup>) mice (46.29 ± 5.13% vs. 27.47 ± 1.92%; p = .0176). This cardioprotective effect of CLU is accompanied by an attenuation of the post-AMI proinflammatory response through a decrease in the expression of proinflammatory cytokines interleukin (IL)-6 and IL-1β, a decrease in phosphorylated nuclear factor kappa B (NF-kB) p65, as well as a decrease in the activation of the nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing 3 (NLRP3) inflammasome. Also, we found that in patients with acute ST-segment elevation myocardial infarction (STEMI), circulating CLU-histone complexes were significantly increased compared to healthy controls (p < .001).</p><p><strong>Conclusions: </strong>From these results, CLU protects the heart from inflammatory injury in AMI and this cardioprotection is due at least in part to its ability to neutralise extracellular histones released from the damaged tissue.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70076"},"PeriodicalIF":4.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in multimodality imaging-guided therapy in pericarditis. 多模态影像引导治疗心包炎的最新进展。
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-23 DOI: 10.1111/eci.70067
Joseph El Roumi, Aldo L Schenone, Paul Cremer, Tom Kai Ming Wang, Allan Klein
{"title":"Recent advances in multimodality imaging-guided therapy in pericarditis.","authors":"Joseph El Roumi, Aldo L Schenone, Paul Cremer, Tom Kai Ming Wang, Allan Klein","doi":"10.1111/eci.70067","DOIUrl":"https://doi.org/10.1111/eci.70067","url":null,"abstract":"<p><strong>Background: </strong>In the era of precision medicine, cardiac multimodality imaging plays a vital role in diagnosing, managing, and monitoring pericarditis. This condition, often marked by inflammation and recurrent episodes, requires precise imaging techniques to guide diagnosis and therapeutic decisions.</p><p><strong>Methods: </strong>We carefully reviewed the medical literature for high-quality data regarding the use of multimodality imaging in pericarditis and the precious value of the novel concept of imaging-guided therapy.</p><p><strong>Results: </strong>While echocardiography remains the cornerstone for detecting pericardial effusion and evaluating hemodynamics, its limited ability to characterize inflammation has driven the use of advanced modalities such as cardiac magnetic resonance imaging (CMR), cardiac computed tomography (CT), and positron emission tomography (PET). CMR offers superior visualization of pericardial inflammation through late gadolinium enhancement, aiding in identifying patients who may benefit from targeted anti-inflammatory therapies. CT imaging, with its high spatial resolution, aids in detecting pericardial calcifications and thickening, particularly in constrictive pericarditis. PET, often combined with CT, is a valuable tool for quantifying metabolic activity, allowing the detection of active inflammation, particularly in complex or refractory cases. Multiple imaging targets have been identified as essential biomarkers to confirm the inflammatory phenotype, assess treatment response, and monitor for complications.</p><p><strong>Conclusion: </strong>Considering the inherent limitations of each imaging modality, the integration of imaging findings with clinical and biomarker data may aid clinicians in tailoring therapy according to different clinical scenarios and better stratification of patients who may benefit from IL-1 blockade. This review explores the valuable role of cardiac multimodality imaging-guided therapy in managing pericarditis.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70067"},"PeriodicalIF":4.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
siRNA-based therapeutics for lipoprotein (a) lowering: A path toward precision cardiovascular medicine. 基于sirna的脂蛋白(a)降低疗法:通往精准心血管医学之路。
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-23 DOI: 10.1111/eci.70079
Mehmet Kanbay, Lasin Ozbek, Mustafa Guldan, Zeynep Y Yilmaz, Alberto Ortiz, Francesca Mallamaci, Carmine Zoccali
{"title":"siRNA-based therapeutics for lipoprotein (a) lowering: A path toward precision cardiovascular medicine.","authors":"Mehmet Kanbay, Lasin Ozbek, Mustafa Guldan, Zeynep Y Yilmaz, Alberto Ortiz, Francesca Mallamaci, Carmine Zoccali","doi":"10.1111/eci.70079","DOIUrl":"https://doi.org/10.1111/eci.70079","url":null,"abstract":"<p><p>Elevated Lp(a) is recognized as a significant independent risk factor for atherosclerotic cardiovascular diseases, including coronary artery disease, stroke and aortic valve stenosis. Notably, Lp(a) exhibits unique pro-inflammatory and pro-thrombotic properties contributing to its pathogenic role in cardiovascular disease. Although interventions targeting interleukin-6 (IL-6) and proprotein convertase subtilisin/kexin type 9 (PCSK9) have been shown to reduce Lp(a) levels, the extent to which this reduction contributes to their overall cardiovascular benefits remains uncertain. Recent clinical trials have demonstrated that small interfering RNA (siRNA) therapies are effective in lowering Lp(a) levels, prompting ongoing investigations into their potential to improve cardiovascular outcomes. These developments highlight the clinical significance of targeting Lp(a) as a therapeutic strategy. This paper offers a comprehensive review of the pathophysiological role of Lp(a) as an independent cardiovascular risk factor, followed by an in-depth analysis of siRNA-based therapeutics designed to target Lp(a). It examines their mechanisms of action, clinical efficacy and safety profiles, while also addressing potential risks, limitations and challenges associated with Lp(a)-modulating siRNA treatments. Additionally, the review discusses other RNA-based therapeutic approaches for Lp(a) reduction, along with an overview of ongoing clinical trials. Finally, future perspectives are considered to assess the evolving therapeutic landscape and the potential advancements in Lp(a)-targeting strategies for improving cardiovascular outcomes.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70079"},"PeriodicalIF":4.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-specific predictive value of reticulated platelets in coronary artery disease: A systematic review and meta-analysis. 网状血小板在冠状动脉疾病中的性别特异性预测价值:一项系统综述和荟萃分析
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-19 DOI: 10.1111/eci.70078
Sebastien Elvinger, Stephanie G Kuehne, Andrea Patrignani, Maximilian Tscharre, Matthias Freynhofer, Leor Perl, Ran Kornowski, Francesca Cesari, Rossella Marcucci, Laura Novelli, Isabell Bernlochner, Philip W Raake, Mauro Chiarito, Dario Bongiovanni
{"title":"Sex-specific predictive value of reticulated platelets in coronary artery disease: A systematic review and meta-analysis.","authors":"Sebastien Elvinger, Stephanie G Kuehne, Andrea Patrignani, Maximilian Tscharre, Matthias Freynhofer, Leor Perl, Ran Kornowski, Francesca Cesari, Rossella Marcucci, Laura Novelli, Isabell Bernlochner, Philip W Raake, Mauro Chiarito, Dario Bongiovanni","doi":"10.1111/eci.70078","DOIUrl":"https://doi.org/10.1111/eci.70078","url":null,"abstract":"<p><strong>Background: </strong>Platelets play a crucial role in immune responses and haemostasis. Among them, reticulated platelets (RPs) have gathered attention for their association with prothrombotic states and as a potential biomarker for cardiovascular events. However, the sex-specific prognostic value of RPs remains underexplored.</p><p><strong>Objective: </strong>This study aimed to systematically review and analyse sex-specific differences in the prognostic role of RPs in cardiovascular disease.</p><p><strong>Methods: </strong>We conducted a comprehensive search on studies that reported patient outcomes related to RPs. Study authors were contacted to provide sex-specific patient-level data. Two studies were excluded due to data unavailability. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE). Secondary endpoints included cardiovascular death, myocardial infarction, stroke, urgent revascularization, and bleeding incidents. All outcomes were stratified by sex.</p><p><strong>Results: </strong>The analysis included 5 studies, reporting outcomes in 1835 patients (527 females and 1308 males). RPs are a significant predictor of MACCE independently of sex males (OR 1.99 [95% CI 1.3, 3.05; I<sup>2</sup> = 29%]), females (2.29 [95% CI 1.31, 3.99; I<sup>2</sup> = 10%]). For cardiovascular death RPs were predictive in females (OR 3.29 [95% CI 1.69, 6.40] I<sup>2</sup> = .83%) and showed a trend toward significance in males (OR 2.19 95% CI [.98, 4.9] I<sup>2</sup> = 42.72%). No sex-specific differences were observed in all other secondary endpoints.</p><p><strong>Conclusion: </strong>RPs significantly predict MACCE in cardiovascular disease independently from sex and may have a stronger association with cardiovascular death in females. Further research is needed to explore the sex-specific mechanisms of RPs' prognostic value.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70078"},"PeriodicalIF":4.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From liver to limb: Exploring the association between fatty liver disease and peripheral artery disease-A systematic review. 从肝脏到肢体:探讨脂肪肝与外周动脉疾病的关系——系统综述。
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-19 DOI: 10.1111/eci.70075
Vera Ciornolutchii, Abdulrahman Ismaiel, Jennifer Bogdan, Stefan-Lucian Popa, Teodora Surdea-Blaga, Dan L Dumitrascu
{"title":"From liver to limb: Exploring the association between fatty liver disease and peripheral artery disease-A systematic review.","authors":"Vera Ciornolutchii, Abdulrahman Ismaiel, Jennifer Bogdan, Stefan-Lucian Popa, Teodora Surdea-Blaga, Dan L Dumitrascu","doi":"10.1111/eci.70075","DOIUrl":"https://doi.org/10.1111/eci.70075","url":null,"abstract":"<p><strong>Introduction: </strong>Fatty liver disease, encompassing nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated fatty liver disease (MAFLD), and the recently redefined metabolic dysfunction-associated steatotic liver disease (MASLD), is a growing global health concern with significant cardiovascular implications. Peripheral artery disease (PAD), a common manifestation of systemic atherosclerosis, shares key pathophysiological mechanisms with fatty liver disease, including insulin resistance, systemic inflammation and endothelial dysfunction. Although emerging evidence suggests a link between fatty liver disease and PAD, the nature and extent of this association remain unclear. This systematic review synthesizes current research evaluating the relationship between fatty liver disease and PAD.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase and Scopus was conducted up to December 19, 2024, following PRISMA 2020 guidelines. Eligible observational studies assessing PAD in MASLD, MAFLD or NAFLD patients were included. Quality assessment was performed independently by two reviewers using the Newcastle-Ottawa Scale (NOS).</p><p><strong>Results: </strong>Eleven observational studies, including approximately 848,027 participants, were analysed. Most studies reported a significant association between NAFLD or MAFLD and increased PAD risk, particularly in individuals with type 2 diabetes and metabolic syndrome. Studies using MAFLD criteria demonstrated a stronger association with PAD than those using NAFLD definitions. The presence of hepatic fibrosis was linked to a higher PAD risk in some studies. However, not all studies found a consistent relationship, and a few reported no independent association between fatty liver disease and PAD, highlighting the need for further research. Notably, none of the included studies used MASLD criteria.</p><p><strong>Conclusions: </strong>Patients with NAFLD or MAFLD, particularly those with metabolic comorbidities, may have an elevated risk of PAD. The severity of liver disease, including fibrosis, appears to contribute to this risk. Future studies should incorporate MASLD definitions and advanced diagnostic methods to clarify this relationship and guide clinical strategies for integrated cardiovascular and liver disease management.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70075"},"PeriodicalIF":4.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aging in focus: A comprehensive view to enhance healthspan 关注老龄化:全面提高健康寿命
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-19 DOI: 10.1111/eci.70057
{"title":"Aging in focus: A comprehensive view to enhance healthspan","authors":"","doi":"10.1111/eci.70057","DOIUrl":"https://doi.org/10.1111/eci.70057","url":null,"abstract":"<p>With great pleasure, we welcome you to the 59th annual scientific meeting of the European Society for Clinical Investigation, in Genoa, Italy, on May 21–23, 2025.</p><p>Gaining awareness on aging as an unavoidable process isn't a defeat but rather a catalyst for contemporary scientific research. While the medical field takes the lead in this endeavour, it's increasingly intertwined with ever-broader areas of science.</p><p>These are the principles we aim to imprint and upon which we work to build an exciting scientific program. We are planning several parallel symposia covering different aspects of aging in human health and disease. Keynote lectures, abstract presentations and pre-meeting courses will compose a consolidated recipe for a successful ESCI meeting.</p><p>Not by chance, Liguria, with Genoa as its capital, has been certified by the European Community as the oldest region in Europe. Long-time aware of this—and a paradigm of the abovementioned concepts—the local government and healthcare system had to rethink the economic activities, environmental management, connectivity and housing to maintain resident well-being.</p><p>Why do people live longer in Liguria? We invite you to discover it! Amazing landscapes, where the mountains meet the sea face to face, a thousand-year history and a cuisine waiting to be discovered. These are some of our secrets that provide an ideal backdrop for 3 days of science, networking and why not, a bit of fun!</p><p>We are happy and proud to have you here as our guests in Genoa!</p><p>\u0000 <b>Luca Liberale</b>\u0000 </p><p>\u0000 <b>Federico Carbone</b>\u0000 </p><p>Department of Internal Medicine, University of Genoa IRCCS Ospedale Policlinico San Martino, Genoa, Italy</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 S2","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70057","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144091312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concordance-discordance between apolipoprotein B and lipid biomarkers in predicting 20-year atherosclerotic cardiovascular disease risk: The ATTICA study (2002-2022). 载脂蛋白B和脂质生物标志物在预测20年动脉粥样硬化性心血管疾病风险中的一致性-不一致性:ATTICA研究(2002-2022)。
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-19 DOI: 10.1111/eci.70077
Sofia-Panagiota Giannakopoulou, Smaragdi Antonopoulou, Fotios Barkas, Evangelos Liberopoulos, Christina Chrysohoou, Petros P Sfikakis, Christos Pitsavos, Costas Tsioufis, Demosthenes Panagiotakos
{"title":"Concordance-discordance between apolipoprotein B and lipid biomarkers in predicting 20-year atherosclerotic cardiovascular disease risk: The ATTICA study (2002-2022).","authors":"Sofia-Panagiota Giannakopoulou, Smaragdi Antonopoulou, Fotios Barkas, Evangelos Liberopoulos, Christina Chrysohoou, Petros P Sfikakis, Christos Pitsavos, Costas Tsioufis, Demosthenes Panagiotakos","doi":"10.1111/eci.70077","DOIUrl":"https://doi.org/10.1111/eci.70077","url":null,"abstract":"<p><strong>Background: </strong>A strong correlation exists between low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B100 (apoB). However, evidence suggests that LDL-C and non-HDL-C may underestimate apoB, potentially obscuring residual cardiovascular risk. Furthermore, interactions between apoB and lipoprotein(a) are implicated in atherogenesis. This study sought to determine whether discordance between apoB, LDL-C, non-HDL-C, or lipoprotein(a) is associated with 20-year atherosclerotic cardiovascular disease (ASCVD) risk within a cohort of apparently healthy adults.</p><p><strong>Methods: </strong>A cohort of 3042 CVD-free adults residing in greater Athens, Greece, was recruited in 2002. A 20-year follow-up was conducted in 2022, comprising n = 2169 participants, of which n = 1988 had complete data for cardiovascular disease incidence. Discordance between biomarkers was defined based on recommended lipid thresholds. Cox proportional hazards models were used to assess the association between discordant/concordant biomarker pairs and 20-year ASCVD risk.</p><p><strong>Results: </strong>ApoB strongly correlated with LDL-C and non-HDL-C, though concordance was limited. Increased 20-year ASCVD cumulative incidence with elevated apoB levels, beyond LDL-C, non-HDL-C, and lipoprotein(a). Discordance analysis revealed that elevated apoB independently predicted increased 20-year ASCVD risk, regardless of non-HDL-C and lipoprotein(a). However, this effect was observed only on concomitantly elevated LDL-C levels. Incorporating apoB into the assessment of traditional modifiable risk factors elucidated part of the previously residual 20-year ASCVD risk, especially in individuals with elevated LDL-C, non-HDL-C, or lipoprotein(a) levels.</p><p><strong>Conclusions: </strong>ApoB may be a superior biomarker for assessing long-term ASCVD risk, indicating that apoB-containing lipoprotein particle number, rather than cholesterol content, is a more robust predictor of ASCVD risk.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70077"},"PeriodicalIF":4.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential effect of triglycerides on the prognosis of patients with a first versus recurrent acute coronary syndrome. 甘油三酯对首次与复发急性冠脉综合征患者预后的差异影响。
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-16 DOI: 10.1111/eci.70072
Alberto Cordero, Rosa Fernandez Olmo, José R González-Juanatey, Leticia A Fernández-Freira, Sergio Manzano, Clara Bonanad, Gustavo Cortez, Armando Oterino, Belen Alvarez-Alvarez, Pedro J Flores Blanco, Jose M Castellano, Deepak L Bhatt
{"title":"Differential effect of triglycerides on the prognosis of patients with a first versus recurrent acute coronary syndrome.","authors":"Alberto Cordero, Rosa Fernandez Olmo, José R González-Juanatey, Leticia A Fernández-Freira, Sergio Manzano, Clara Bonanad, Gustavo Cortez, Armando Oterino, Belen Alvarez-Alvarez, Pedro J Flores Blanco, Jose M Castellano, Deepak L Bhatt","doi":"10.1111/eci.70072","DOIUrl":"https://doi.org/10.1111/eci.70072","url":null,"abstract":"<p><strong>Background: </strong>There is divergent evidence of triglycerides on cardiovascular prevention that might be explained by confounding factors.</p><p><strong>Methods: </strong>We performed a multicenter and retrospective study using the ongoing registries of acute coronary syndrome (ACS) patients of 8 hospitals from Spain. Triglycerides were measured during the hospitalization, and mortality and major adverse cardiovascular events (MACE) were analysed through follow-up.</p><p><strong>Results: </strong>We included 14,483 patients discharged after an ACS. Median triglycerides level was 120.5 (interquartile range [IQRS] 90-197) mg/dL and was slightly higher in patients with recurrent ACS (135 IQR 98-186 vs. 129 IQR 95-175; p < .01). Through the follow-up, 34.7% of the patients experienced a first MACE rate and 15.0% died. Multivariate analysis identified that triglycerides levels were associated with a higher risk of MACE (HR 1.01 95% CI 1.00-1.02, p = .021) but not with all-cause mortality (HR: 1.00 95% .99-1.02, p = .17). A significant interaction (p = .01) was observed for triglycerides and previous ACS for both endpoints and, therefore, analyses were performed separately. Triglycerides were only associated with a higher risk of MACE in patients with recurrent ACS (HR 1.03 95% CI 1.01-1.05, p = .012) and a higher risk of death in patients with a first ACS (HR 1.02 95% CI 1.01-1.04, p = .02).</p><p><strong>Conclusions: </strong>Previous ACS modifies the risk of triglycerides on MACE and mortality in patients discharged after an ACS. Triglycerides might be considered a target for treatment in patients after a first or recurrent ACS, although the expected benefit on outcomes might be different.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70072"},"PeriodicalIF":4.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential effects of bariatric surgery on circulating GDF15 and FGF21 levels: Implications for glycemic status and weight loss outcomes. 减肥手术对循环GDF15和FGF21水平的不同影响:对血糖状态和减肥结果的影响
IF 4.4 3区 医学
European Journal of Clinical Investigation Pub Date : 2025-05-16 DOI: 10.1111/eci.70069
Laura Salmón-Gómez, Victoria Catalán, Beatriz Ramírez, Maite Aguas-Ayesa, Amaia Rodríguez, Sara Becerril, Víctor Valentí, Rafael Moncada, Carolina M Perdomo, Camilo Silva, Javier Escalada, Gema Frühbeck, Javier Gómez-Ambrosi
{"title":"Differential effects of bariatric surgery on circulating GDF15 and FGF21 levels: Implications for glycemic status and weight loss outcomes.","authors":"Laura Salmón-Gómez, Victoria Catalán, Beatriz Ramírez, Maite Aguas-Ayesa, Amaia Rodríguez, Sara Becerril, Víctor Valentí, Rafael Moncada, Carolina M Perdomo, Camilo Silva, Javier Escalada, Gema Frühbeck, Javier Gómez-Ambrosi","doi":"10.1111/eci.70069","DOIUrl":"https://doi.org/10.1111/eci.70069","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes (T2D) is a comorbidity commonly associated with obesity. Elevated concentrations of growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21) are associated with these conditions, making both cytokines interesting candidates to combat them. This study aimed to analyse the relationship between changes in plasma GDF15 and FGF21 levels and the resolution of T2D or obesity improvements after bariatric surgery.</p><p><strong>Methods: </strong>Plasma samples from 104 patients (52 with obesity and normoglycemia and 52 with obesity and impaired glucose tolerance or T2D) were analysed before and after Roux-en-Y-gastric bypass surgery.</p><p><strong>Results: </strong>Plasma GDF15 levels increased significantly after bariatric surgery in patients with obesity and normoglycemia (p < 0.01), as well as in those with obesity and impaired glucose tolerance or T2D (p < 0.05). This increase was significant in patients analysed up to 8 months after surgery in both groups (p < 0.01) but not in those analysed between 8 to 15 months after surgery, suggesting that GDF15 concentrations exhibit an early increase after surgery but may return to baseline levels over time. In contrast, plasma FGF21 levels after bariatric surgery decreased significantly in patients with impaired glucose tolerance or T2D (p < 0.05). Pre-surgery FGF21 concentrations were negatively correlated with the percentage of excess weight loss and the percentage of fat loss.</p><p><strong>Conclusions: </strong>GDF15 and FGF21 exhibit a different behaviour after Roux-en-Y-gastric bypass surgery, with FGF21 being more closely associated with glycemic status and weight loss. Elevated pre-surgery FGF21 concentrations could predict a higher difficulty in losing the excess weight after surgery.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70069"},"PeriodicalIF":4.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信